tezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer.Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response.
中文別名:
阿特朱單抗; 達(dá)雷木單抗
其他
適應(yīng)癥：
阿特朱單抗用于治療在含鉑化療期間或之后病情惡化的轉(zhuǎn)移性非小細(xì)胞肺癌。
藥理作用及作用機(jī)制：
PD-L1可能被表達(dá)腫瘤細(xì)胞和/或腫瘤浸潤免疫細(xì)胞上和可能對在腫瘤微環(huán)境中抗腫瘤免疫反應(yīng)的抑制作用有貢獻(xiàn)。PD-L1的結(jié)合至T細(xì)胞上發(fā)現(xiàn)PD-1和B7.1受體和抗原提呈細(xì)胞抑制細(xì)胞毒性T細(xì)胞活性，T-細(xì)胞增殖和細(xì)胞因子產(chǎn)生。阿特朱單抗是一個單克隆抗體結(jié)合至PD-L1和阻斷它的與PD-1和B7.1受體兩者相互作用。這個釋放PD-L1/PD-1介導(dǎo)的免疫反應(yīng)的抑制作用，包括抗腫瘤免疫反應(yīng)的活化無誘導(dǎo)抗體依賴細(xì)胞細(xì)胞毒性。在同源小鼠腫瘤模型中，阻斷PD-L1活性導(dǎo)致腫瘤生長減低。
采購中心
